Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy |
| |
| Authors: | Angenault Stéphane Thirot Sylvie Schmidt Frédéric Monneret Claude Pfeiffer Bruno Renard Pierre |
| |
| Affiliation: | UMR176 CNRS/Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05, France. |
| |
| Abstract: | A glucuronide-based prodrug of SN-38 (7-ethyl-10-hydroxycamptothecin) has been synthesized for use in a Prodrug MonoTherapy Strategy (PMT). Since this prodrug is significantly less cytotoxic than SN-38 itself and efficiently releases the drug in vitro in the presence of beta-D-glucuronidase, it can be considered as an appropriate candidate for cancer treatment by a PMT strategy. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
